Profound Medical Analyst Price Targets - Benzinga

Profound Medical Corp

PROFNASDAQ

Trade with Public

Trade with Public

$6.92

0.010.14%

마지막 업데이트: Oct 9, 9:29 AM

$6.92

0.010.14%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Profound Medical Analyst Price Targets - Benzinga

Profound Medical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Profound Medical (PROF).

Price Target Range — 5 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingBuy# Analysts3Avg. Consensus PT$12Upside to Avg. PT+67.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jan 7, 2026	Lake Street	Benjamin Haynor	PT Raise	Buy	$11→$12
Apr 23, 2025	Lake Street	Benjamin Haynor	PT Cut	Buy	$17→$11
Jul 16, 2024	Stifel	Rick Wise	Upgrade	Hold→Buy	$9→$12
Mar 11, 2024	Alliance Global Partners	Ben Haynor	PT Cut	Buy	$13→$11
Mar 8, 2024	Stifel	Rick Wise	PT Cut	Hold	$11→$9
Jan 4, 2024	Alliance Global Partners	Ben Haynor	PT Cut	Buy	$14→$13
Nov 28, 2023	Stifel	Rick Wise	Initiate	Hold	$11

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Lake Street Maintains Buy on Profound Medical, Raises Price Target to $12

Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and raises the price target from $11 to $12.

Benzinga Newsdesk

PRO
Lake Street Maintains Buy on Profound Medical, Lowers Price Target to $11

Lake Street analyst Benjamin Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target from $17 to $11.

Benzinga Newsdesk

Microsoft To Rally Around 6%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

PRO
Stifel Upgrades Profound Medical to Buy, Raises Price Target to $12

Stifel analyst Rick Wise upgrades Profound Medical (NASDAQ:PROF) from Hold to Buy and raises the price target from $9 to $12.

Benzinga Newsdesk

PRO
Alliance Global Partners Maintains Buy on Profound Medical, Lowers Price Target to $10.8

Alliance Global Partners analyst Ben Haynor maintains Profound Medical (NASDAQ:PROF) with a Buy and lowers the price target from $12.75 to $10.8.

Benzinga Newsdesk

PRO
Stifel Maintains Hold on Profound Medical, Lowers Price Target to $9

Stifel analyst Rick Wise maintains Profound Medical (NASDAQ:PROF) with a Hold and lowers the price target from $11 to $9.

Benzinga Newsdesk